Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1973 2
1974 1
1975 1
1976 5
1977 4
1978 2
1979 4
1980 2
1981 2
1983 2
1986 3
1987 1
1988 5
1989 3
1990 6
1991 7
1993 4
1994 2
1995 4
1996 1
1997 1
1998 2
2000 1
2001 1
2005 3
2008 2
2009 3
2010 4
2011 10
2012 4
2013 4
2014 2
2015 4
2016 6
2017 7
2018 11
2019 23
2020 32
2021 38
2022 45
2023 59
2024 21

Text availability

Article attribute

Article type

Publication date

Search Results

317 results

Results by year

Filters applied: . Clear all
Page 1
The Role of Cannabidiol in Liver Disease: A Systemic Review.
Chen S, Kim JK. Chen S, et al. Int J Mol Sci. 2024 Feb 17;25(4):2370. doi: 10.3390/ijms25042370. Int J Mol Sci. 2024. PMID: 38397045 Free PMC article. Review.
Cannabidiol (CBD), a non-psychoactive phytocannabinoid abundant in Cannabis sativa, has gained considerable attention for its anti-inflammatory, antioxidant, analgesic, and neuroprotective properties. It exhibits the potential to prevent or slow the progression of various
Cannabidiol (CBD), a non-psychoactive phytocannabinoid abundant in Cannabis sativa, has gained considerable attention for its anti-in
Cannabidiol Adverse Effects and Toxicity.
Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Huestis MA, et al. Curr Neuropharmacol. 2019;17(10):974-989. doi: 10.2174/1570159X17666190603171901. Curr Neuropharmacol. 2019. PMID: 31161980 Free PMC article. Review.
BACKGROUND: Currently, there is a great interest in the potential medical use of cannabidiol (CBD), a non-intoxicating cannabinoid. Productive pharmacological research on CBD occurred in the 1970s and intensified recently with many discoveries about the endocannabinoid sys …
BACKGROUND: Currently, there is a great interest in the potential medical use of cannabidiol (CBD), a non-intoxicating cannabinoid. P …
Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.
Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, Greenwood SM, Roberts C, Checketts D, VanLandingham KE, Zuberi SM; GWPCARE3 Study Group. Devinsky O, et al. N Engl J Med. 2018 May 17;378(20):1888-1897. doi: 10.1056/NEJMoa1714631. N Engl J Med. 2018. PMID: 29768152 Free article. Clinical Trial.
Fourteen patients who received cannabidiol (9%) had elevated liver aminotransferase concentrations. ...Adverse events with cannabidiol included elevated liver aminotransferase concentrations. ...
Fourteen patients who received cannabidiol (9%) had elevated liver aminotransferase concentrations. ...Adverse events with …
Cannabidiol markedly alleviates skin and liver fibrosis.
Del Río C, Ruiz-Pino F, Prados ME, Fiebich BL, Tena-Sempere M, Muñoz E. Del Río C, et al. Front Pharmacol. 2022 Oct 19;13:981817. doi: 10.3389/fphar.2022.981817. eCollection 2022. Front Pharmacol. 2022. PMID: 36339540 Free PMC article.
Cannabidiol was demonstrated to reduce alcohol-induced liver inflammation and steatosis but its specific activity on the fibrotic process was not investigated. ...In a second model, non-alcoholic liver fibrosis was induced in mice by CCl(4) exposure. Canna
Cannabidiol was demonstrated to reduce alcohol-induced liver inflammation and steatosis but its specific activity on the fibro
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S; Cannabidiol in Dravet Syndrome Study Group. Devinsky O, et al. N Engl J Med. 2017 May 25;376(21):2011-2020. doi: 10.1056/NEJMoa1611618. N Engl J Med. 2017. PMID: 28538134 Free article. Clinical Trial.
The percentage of patients who became seizure-free was 5% with cannabidiol and 0% with placebo (P=0.08). Adverse events that occurred more frequently in the cannabidiol group than in the placebo group included diarrhea, vomiting, fatigue, pyrexia, somnolence, and ab …
The percentage of patients who became seizure-free was 5% with cannabidiol and 0% with placebo (P=0.08). Adverse events that occurred …
Cannabidiol in canine epilepsy.
Potschka H, Bhatti SFM, Tipold A, McGrath S. Potschka H, et al. Vet J. 2022 Dec;290:105913. doi: 10.1016/j.tvjl.2022.105913. Epub 2022 Oct 6. Vet J. 2022. PMID: 36209995 Free article.
The anticonvulsant effect of cannabidiol (CBD), which has been confirmed by findings from animal models and human trials, has attracted the interest of veterinary practitioners and dog owners. ...Pharmacokinetic studies in dogs have demonstrated a low oral bioavailability …
The anticonvulsant effect of cannabidiol (CBD), which has been confirmed by findings from animal models and human trials, has attract …
Cannabidiol.
[No authors listed] [No authors listed] 2023 Feb 16. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2023 Feb 16. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31644197 Free Books & Documents. Review.
High daily doses of cannabidiol are associated with frequent serum enzyme elevations during therapy, but has not been linked to cases of clinically apparent liver injury with jaundice. The lower doses of cannabidiol found typically in over-the-counter CBD pro …
High daily doses of cannabidiol are associated with frequent serum enzyme elevations during therapy, but has not been linked to cases …
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial.
Thiele EA, Bebin EM, Bhathal H, Jansen FE, Kotulska K, Lawson JA, O'Callaghan FJ, Wong M, Sahebkar F, Checketts D, Knappertz V; GWPCARE6 Study Group. Thiele EA, et al. JAMA Neurol. 2021 Mar 1;78(3):285-292. doi: 10.1001/jamaneurol.2020.4607. JAMA Neurol. 2021. PMID: 33346789 Free PMC article. Clinical Trial.
Twenty-eight patients taking cannabidiol (18.9%) had elevated liver transaminase levels vs none taking placebo. CONCLUSIONS AND RELEVANCE: Cannabidiol significantly reduced TSC-associated seizures compared with placebo. ...
Twenty-eight patients taking cannabidiol (18.9%) had elevated liver transaminase levels vs none taking placebo. CONCLUSIONS AN …
A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential.
White CM. White CM. J Clin Pharmacol. 2019 Jul;59(7):923-934. doi: 10.1002/jcph.1387. Epub 2019 Feb 7. J Clin Pharmacol. 2019. PMID: 30730563 Review.
Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. ...CBD is not risk free, with adverse events (primarily somnolence and gastrointestinal in nature) and drug interactions. CBD has been shown to increase liver function tes
Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. ...CBD is not risk free, with adverse
Assessing Liver Effects of Cannabidiol and Valproate Alone and in Combination Using Quantitative Systems Toxicology.
Lakhani VV, Generaux G, Howell BA, Longo DM, Watkins PB. Lakhani VV, et al. Clin Pharmacol Ther. 2023 Nov;114(5):1006-1014. doi: 10.1002/cpt.3004. Epub 2023 Jul 28. Clin Pharmacol Ther. 2023. PMID: 37458709
In clinical trials of cannabidiol (CBD) for the treatment of seizures in patients with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex, elevations in serum alanine aminotransferase (ALT) > 3 the upper limit of normal were observed in some patent …
In clinical trials of cannabidiol (CBD) for the treatment of seizures in patients with Dravet syndrome, Lennox-Gastaut syndrome, and …
317 results